See more : Black Knight, Inc. (BKI) Income Statement Analysis – Financial Results
Complete financial analysis of REGENXBIO Inc. (RGNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of REGENXBIO Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jiangsu Dagang Co., Ltd. (002077.SZ) Income Statement Analysis – Financial Results
- Electric Power Development Co., Ltd. (EDRWY) Income Statement Analysis – Financial Results
- European Assets Trust PLC (EAT.L) Income Statement Analysis – Financial Results
- Mobile TeleSystems Public Joint Stock Company (MBT) Income Statement Analysis – Financial Results
- Inani Marbles and Industries Limited (INANI.BO) Income Statement Analysis – Financial Results
REGENXBIO Inc. (RGNX)
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.24M | 112.72M | 470.35M | 154.57M | 35.23M | 218.51M | 10.39M | 4.59M | 7.59M | 6.12M | 6.09M |
| Cost of Revenue | 37.21M | 54.55M | 51.83M | 35.71M | 8.24M | 9.64M | 1.71M | 959.00K | 1.50M | 1.01M | 324.00K |
| Gross Profit | 53.03M | 58.18M | 418.51M | 118.85M | 26.99M | 208.87M | 8.68M | 3.63M | 6.09M | 5.11M | 5.76M |
| Gross Profit Ratio | 58.76% | 51.61% | 88.98% | 76.89% | 76.61% | 95.59% | 83.56% | 79.10% | 80.19% | 83.55% | 94.68% |
| Research & Development | 232.27M | 242.45M | 181.44M | 166.29M | 124.19M | 83.87M | 57.22M | 45.48M | 17.28M | 4.96M | 5.05M |
| General & Administrative | 88.49M | 85.28M | 79.33M | 63.82M | 51.82M | 36.85M | 27.23M | 23.59M | 11.91M | 3.85M | 5.47M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 88.49M | 85.28M | 79.33M | 63.82M | 51.82M | 36.85M | 27.23M | 23.59M | 11.91M | 3.85M | 5.47M |
| Other Expenses | 397.00K | -6.68M | -2.24M | 7.98M | -10.00K | 42.00K | 116.00K | -102.00K | -26.00K | -47.00K | 0.00 |
| Operating Expenses | 321.16M | 321.06M | 258.53M | 238.09M | 175.99M | 120.77M | 84.57M | 68.97M | 29.17M | 8.77M | 10.53M |
| Cost & Expenses | 358.37M | 375.60M | 310.37M | 273.80M | 184.23M | 130.41M | 86.28M | 69.93M | 30.67M | 9.77M | 10.85M |
| Interest Income | 25.00K | 342.00K | 719.00K | 4.27M | 2.95M | 8.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.86M | 23.25M | 26.28M | 771.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.00K | 321.00K | 611.00K |
| Depreciation & Amortization | 17.32M | 12.91M | 9.56M | 8.41M | 7.15M | 3.98M | 2.69M | 544.00K | 80.00K | 30.00K | 14.00K |
| EBITDA | -239.46M | -244.24M | 169.54M | -96.83M | -90.34M | 92.08M | -73.20M | -64.80M | -22.71M | -3.65M | -4.78M |
| EBITDA Ratio | -265.36% | -232.90% | 34.17% | -74.38% | -560.72% | 37.08% | -756.29% | -1,423.84% | -304.16% | -59.67% | -78.23% |
| Operating Income | -268.13M | -262.88M | 159.98M | -119.23M | -149.00M | 88.10M | -75.89M | -65.34M | -23.14M | -3.68M | -4.78M |
| Operating Income Ratio | -297.12% | -233.20% | 34.01% | -77.14% | -422.89% | 40.32% | -730.15% | -1,423.84% | -304.92% | -60.16% | -78.46% |
| Total Other Income/Expenses | 4.48M | -17.53M | -18.73M | 13.22M | 51.51M | 16.02M | 2.72M | 1.94M | 326.00K | -321.00K | -611.00K |
| Income Before Tax | -263.65M | -280.41M | 141.25M | -106.01M | -97.49M | 104.12M | -73.17M | -63.40M | -22.81M | -4.00M | -5.39M |
| Income Before Tax Ratio | -292.15% | -248.75% | 30.03% | -68.59% | -276.70% | 47.65% | -704.02% | -1,381.61% | -300.62% | -65.41% | -88.50% |
| Income Tax Expense | -152.00K | -84.00K | 13.41M | 5.24M | -2.76M | 4.18M | 686.00K | -435.00K | -60.00K | 291.00K | 597.00K |
| Net Income | -263.49M | -280.32M | 127.84M | -111.25M | -94.73M | 99.94M | -73.17M | -62.97M | -22.81M | -4.00M | -5.39M |
| Net Income Ratio | -291.99% | -248.68% | 27.18% | -71.98% | -268.88% | 45.74% | -704.02% | -1,372.13% | -300.62% | -65.41% | -88.50% |
| EPS | -6.02 | -6.50 | 3.01 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.30 | -0.41 |
| EPS Diluted | -6.02 | -6.50 | 2.91 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.30 | -0.41 |
| Weighted Avg Shares Out | 43.73M | 43.15M | 42.44M | 37.28M | 36.69M | 36.61M | 29.86M | 26.41M | 9.17M | 13.15M | 13.15M |
| Weighted Avg Shares Out (Dil) | 43.73M | 43.15M | 43.91M | 37.28M | 36.69M | 36.65M | 29.88M | 26.41M | 9.17M | 13.15M | 13.15M |
Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Source: https://incomestatements.info
Category: Stock Reports